CC BY
25
Получена: 4 ноября 2020 / Принята: 8 января 2021 / Опубликована online: 30 марта 2021 DOI 10.34689/SH.2021.23.1.001 УДК 616.98-036.21:578.834.1
ANALYSIS OF THE IMPLEMENTATION OF CLINICAL MANIFESTATIONS OF COVID-19 IN CONTACT PERSONS
Aitolkyn Mynzhanova 1, https://orcid.org/0000-0002-3015-4153
Dinagul A. Baesheva 1<2, https://orcid.org/0000-0001-9129-5825
Aliya K. Omarova 1'2, Meruert O. Khamitova 1'2, Aiganym U. Daulbaeva 1'2
Bayan R. Turdalina 1,2, https://orcid.org/0000-0002-5219-0753
Aliya J. Seydullaeva 1<2, https://orcid.org/0000-0002-7513-5677
Aygerim A. Zhuzzhasarova1, https://orcid.org/0000-0001-6556-4489
Alyona V. Altynbekova 1,2, https://orcid.org/0000-0002-4407-4525
Ulyana A. Kirpicheva 3,
Almagul А. Kushugulova 4, https://orcid.org/0000-0001-9479-0899 Samat S. Kozhakhmetov 4<5, https://orcid.org/0000-0001-9668-0327
1 NJSC "Medical University Astana", Nur-Sultan, Republic of Kazakhstan;
2 Multidisciplinary City Children's Hospital № 3, Nur-Sultan, Republic of Kazakhstan;
3 "Scientific-practical center of sanitary-epidemiological examination and monitoring" of RSE on PVC "National center of public health" MH RK, Nur-Sultan, Republic of Kazakhstan ;
4 National Laboratory Astana, Nazarbayev University, Nur-Sultan, Republic of Kazakhstan;
5 ArtScience Innovative Center, Nur-Sultan, Republic of Kazakhstan.
Abstract
Introduction. The emergence of a new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus, which first appeared in December 2019, has led to a rapid spread and a global pandemic with 103 million cases reported worldwide. The clinical picture of COVID-19 develops within 14 days after infection, on average, 97,5% of people experience symptoms within 11.5 days. COVID-19 can progress from asymptomatic infection to extremely severe, critical (acute respiratory failure (ARF), acute respiratory distress syndrome (ARDS), shock, multiple organ failure syndrome (MOFS)).
Purpose of the study. To investigate the age characteristics, comorbidities and timing of the main clinical symptoms of COVID-19 in contact patients.
Methods. A retrospective study was carried out, including the collection of clinical data from electronic medical records of patients with COVID-19 who were hospitalized from March 13 to June 5, 2020, taken from the Integrated Medical Information System (CMIS) from all regions of Kazakhstan. The data obtained were processed by descriptive statistics methods.
Results. We analyzed 5326 electronic medical records of patients with COVID-19, of which 94,4% (n = 5011) patients at the time of laboratory confirmation (PCR +) had clinical manifestations of COVID-19 of varying severity, and the remaining 315 were hospitalized as contact persons with positive PCR SARS-CoV-2, in the process of further monitoring it was found that 5,6% of patients realized clinical manifestations of COVID-19 of varying severity during the period of inpatient treatment.
Conclusions. Early detection and monitoring of contact persons with COVID-19 allows the identification of patients from the "risk group" and timely treatment, which helps to reduce the risk of complications. Patients with a mild and asymptomatic course pose a high risk in the continuation of the pandemic and are the cause of a severe epidemiological situation. The results obtained show the importance of early detection, isolation and monitoring of persons in contact with COVID-19. This study with reliable and timely information obtained contributes to timely preventive, therapeutic and diagnostic measures, which contributes to a significant reduction in deaths among people of the "risk group".
Key words: coronavirus infection, COVID-19, clinical manifestations, asymptomatic course.
Резюме
АНАЛИЗ РЕАЛИЗАЦИИ КЛИНИЧЕСКИХ ПРОЯВЛЕНИЙ COVID-19
У КОНТАКТНЫХ ЛИЦ
Айтолкын Мынжанова 1, https://orcid.org/0000-0002-3015-4153
Динагуль А.Баешева 1,2, https://orcid.org/0000-0001-9129-5825
Алия К. Омарова12, Меруерт О. Хамитова 1,2, Айганым У. Даулбаева 1,2
Баян Р. Турдалина 1'2, https://orcid.org/0000-0002-5219-0753
Алия Ж. Сейдуллаева 1'2, https://orcid.org/0000-0002-7513-5677 Айгерим А. Жузжасарова1, https://orcid.org/0000-0001-6556-4489 Алёна В. Алтынбекова 1,2, https://orcid.org/0000-0002-4407-4525 Ульяна А. Кирпичева 3
Алмагуль А. Кушугулова 4, https://orcid.org/0000-0001-9479-0899 Самат С. Кожахметов 4,5 , https://orcid.org/0000-0001-9668-0327
1 НАО «Медицинский университет Астана», г. Нур-Султан, Республика Казахстан;
2 Многопрофильная городская детская больница №3, г. Нур-Султан, Республика Казахстан;
3 «Научно-практический центр санитарно-эпидемиологической экспертизы и мониторинга» РГП на ПХВ «Национальный центр общественного здравоохранения» МЗ РК, г. Нур-Султан, Республика Казахстан;
4 Центр наук о жизни, ЧУ «National Laboratory Astana», Назарбаев Университет, г. Нур-Султан, Республика Казахстан;
5 Инновационный центр ArtScience, г. Нур-Султан, Республика Казахстан.
Резюме
Введение. Появление новой коронавирусной инфекции (COVID-19), вызванной вирусом SARS-CoV-2, впервые появившейся в декабре 2019 г., привело к быстрому распространению и глобальной пандемии с 103 млн. случаев, которые регистрировались во всех странах мира. Клиническая картина COVID - 19 развивается в течение 14 дней после заражения, в среднем у 97,5% людей симптомы реализуются в течение 11,5 дней. COVID-19 может протекать от бессимптомной инфекции до крайне тяжелой, критической (острая дыхательная недостаточность (ОДН), острый респираторный дистресс синдром (ОРДС), шок, синдром полиорганной недостаточности (СПОН)).
Цель исследования. Исследовать возрастную характеристику, сопутствующую патологию и сроки реализации основных клинических симптомов COVID-19, у контактных пациентов.
Методы. Проведено ретроспективное исследование, включающее сбор клинических данных с электронных историй болезней пациентов с COVID-19, находившихся на стационарном лечении с 13 марта по 5 июня 2020 г., взятых из Комплексной медицинской информационной системы (КМИС) со всех регионов Казахстана. Полученные данные обработаны методами описательной статистики.
Результаты. Нами проанализированы 5326 электронных историй болезней пациентов с COVID-19, из них 94.4% (n=5011) пациентов на момент лабораторного подтверждения (ПЦР+) имели клиническую манифестацию COVID-19 различной степени выраженности, а остальные 315 были госпитализированы, как контактные лица с положительным ПЦР SARS-CoV-2, в процессе дальнейшего мониторинга было установлено, что 5,6 % пациентов реализовали клинические проявления COVID-19 различной степени тяжести в период стационарного лечения.
Выводы. Раннее выявление и мониторинг контактных лиц с COVID-19 позволяют выявить пациентов из «группы риска» и провести своевременное лечение, что способствует снижению риска осложнений. Пациенты с легким и бессимптомным течением представляют высокий риск в продолжении пандемии и являются причиной тяжелой эпидемиологической ситуации. Полученные результаты показывают значимость раннего выявления, изоляции и мониторинга лиц, контактных COVID-19. Данное исследование с достоверной и своевременно полученной информацией способствует своевременным профилактическим и лечебно-диагностическим мероприятиям, что способствует существенному снижению летальных исходов среди лиц «группы риска». Ключевые слова: коронавирусная инфекция, COVID-19, клинические проявления, асимптомное течение.
Туйшдеме
БАЙЛАНЫСТА БОЛГАН АДАМДАРДА COVID-19 КЛИНИКАЛЫК К0Р1Н1СТЕР1ЖН 1СКЕ АСЫРЫЛУЫН ТАЛДАУ
Айтолкын Мынжанова 1, https://orcid.org/0000-0002-3015-4153
Динагуль А.Баешева 1<2, https://orcid.org/0000-0001-9129-5825
Алия К. Омарова12, Меруерт О. Хамитова 1,2, Айганым У. Даулбаева 1,2
Баян Р. Турдалина 1<2, https://orcid.org/0000-0002-5219-0753
Алия Ж. Сейдуллаева 1<2, https://orcid.org/0000-0002-7513-5677
Айгерим А. Жузжасарова1, https://orcid.org/0000-0001-6556-4489
Алёна В. Алтынбекова 1'2, https://orcid.org/0000-0002-4407-4525
Ульяна А. Кирпичева 3
Алмагуль А. Кушугулова 4, https://orcid.org/0000-0001-9479-0899 Самат С. Кожахметов 4-5 , https://orcid.org/0000-0001-9668-0327
1 КеАК «Астана медицина университет», Нур-Султан к-, Казахстан Республикасы;
2 Кenбейiндi калалык балалар ауруханасы №3, Нур-Султан к-, Казакстан Республикасы;
3 КР ДСМ "Когамдык денсаулык сактау улттык орталыгы" ШЖК РМК "Санитариялык-эпидемиологиялык сараптама жэне мониторинг гылыми-практикалык орталыгы";
4 @мiр туралы гылымдар орталыгы ЖМ "National Laboratory Astana" Назарбаев Университет^ НурСултан к-, Казакстан Республикасы;
5 ArtScience инновациялык орталыгы, Нур-Султан к-, Казакстан Республикасы.
Kipicne. Алгаш рет 2019 жылдыч желтоксанында пайда болган SARS-CoV-2 вирусынан туындаган жача коронавирустык инфекцияныч (COVID-19) пайда болуы 8лемнщ барлык елдерiнде фкелген 103 миллион жагдаймен тез таралуына ж8не жаhандык пандемияга 8келдi. Covid - 19 клиникалык кврiнiсi инфекциядан кешн 14 кYн iшiнде дамиды, адамдардыч орташа 97,5% - ында 11,5 кYн iшiнде белгiлер байкалады. COVID-19 асимптоматикалык инфекциядан вте ауыр, критикалык (жедел тыныс жетiспеушiлiгi, жедел респираторлы к стресс синдромы, шок, квп агзалы жетiспеушiлiк синдромы) болуы мYмкiн.
Зерттеу максаты. Байланыста болган пациенттерде жас ерекшелИн, катар жYретiн патологияны ж8не COVID-19 непзп клиникалык симптомдарыныч iске асырылу мерзiмiн зерттеу.
Эдicтepi. ^азакстанныщ барлык вфлерЫен кешендi медициналык акпараттык жYЙеден (КМАЖ) алынган 2020 жылгы 13 наурыз бен 5 маусым аралыгында стационарлык емделуде болган COVID-19 бар пациенттердщ электрондык ауру тарихыныч клиникалык деректерЫ жинауды камтитын ретроспективтi зерттеу жYргiзiлдi. Алынган м8лiметтер сипаттамалык статистика 8дiстерiмен вчделедк
Нэтижeлepi. Бiз covid-19 бар пациенттердщ 5326 электрондык ауру тарихын талдадык, олардыч 94.4% (n=5011) зертханалык растау кезiнде (ПТР+) пациенттердщ 8ртYрлi д8режедегi COVID-19 клиникалык манифестациясы болды, ал калган 315-i SARS-CoV-2 оч ПТР-мен байланыста болган адамдар ретще ауруханага жаткызылды, одан 8рi мониторинг процесЫде пациенттердщ 5,6 % стационарлык емдеу кезечще 8ртYрлi ауырлыктагы COVID-19 клиникалык кврУстерЫ жYзеге асырганы аныкталды.
Тужырымдар. COVID-19-бен байланыста болган адамдарды ерте аныктау ж8не бакылау "каут тобындагы" пациенттердi аныктауга ж8не уактылы емделуге мYмкiндiк бередi, бул аскыну каупiн азайтуга квмектеседi. Жечт ж8не асимптоматикалык курспен ауыратын наукастар пандемияныч жалгасуында жогары кауiп тудырады ж8не ауыр эпидемиологиялык жагдайдыч себебi болып табылады. Алынган н8тижелер COVID-19 байланысатын адамдарды ерте аныктау, окшаулау ж8не бакылаудыч мачыздылыгын кврсетедi. Дурыс ж8не уактылы алынган акпараты бар осы зерттеу уактылы алдын алу ж8не емдеу-диагностикалык iс-шараларFа ыкпал етедi, бул "т8уекел тобындагы" адамдар арасындаFы влiм-жiтiмдi ед8уiр твмендетуге ыкпал етедi.
TYurndi свздер: коронавирустык инфекция, COVID-19, клиникалык квршютер, асимптоматикалык курс.
Библиографическая ссылка:
Mynzhanova A., Baesheva D.A., Omarova A.K., Khamitova M.O., Daulbaeva A.U., Turdalina B.R., Seidullayeva A.Zh., Zhuzzhasarova A.A., Altynbekova A.V., Kirpicheva U.A., Kushugulova A.A., Kozhakhmetov S.S. Analysis of the implementation of clinical manifestations of COVID-19 in contact persons // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, 1 (Vol.23), pp. 5-14. doi 10.34689/SH.2021.23.1.001
Мынжанова А., БаешеваД.А., Омарова А.К., Хамитова М.О., Даулбаева А.У., Турдалина Б.Р., Сейдуллаева А.Ж., Жузжасарова А.А., Алтынбекова А.В., Кирпичева У.А. Кушугулова А.А., Кожахметов С.С. Анализ реализации клинических проявлений COVID-19 у контактных лиц // Наука и Здравоохранение. 2021. 1 (Т.23). С. 5-14. doi: 10.34689/SH.2021.23.1.001
Мынжанова А., Баешева Д.А., Омарова А.К., Хамитова М.О., Даулбаева А.У., Турдалина Б.Р., Сейдуллаева А.Ж., Жузжасарова А.А., Алтынбекова А.В., Кирпичева У.А. Кушугулова А.А., Кожахметов С.С. Байланыста болган адамдарда COVID-19 клиникалык кврУстерУч юке асырылуын талдау // Гылым ж8не Денсаулык сактау. 2021. 1 (Т.23). Б. 5-14. doi:10.34689/SH.2021.23.1.001
Introduction
The emergence of a new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus, which first appeared in December 2019, (Wuhan, China) led to a rapid spread and a global pandemic with 103 million cases reported in all countries of the world [8].
According to official statistics to date, in the United States of America (USA), the incidence rate has reached 26 million people, of which the mortality rate is 2,1%. [27]. Italy has 2.54 million registered cases, with a death rate of 3.8%. Data for the Russian Federation (RF) show 3.79 million people, with a death rate of 2.2%. In the Republic of Kazakhstan (RK), the first cases of COVID-19 (SARS-CoV-
2) were registered on March 13, 2020 and today, according to statistics, the number of cases has increased to 235,000, of which approximately 1,5-2% are children, the mortality rate was 1,5% of the total number of cases. This infection, taking into account its molecular and biological features, and the variability of the clinical course, is associated with a high risk of developing critical conditions, complications, and high mortality [5].
The disease patterns of COVID - 19 develops within 14 days after infection, on average, 97.5% of people have symptoms of infection within 11,5 days [8,5,15]. The symptoms of COVID - 19 vary from an asymptomatic infection to an extremely severe, critical one (AHRF, ARDS,
shock, MODS) [5,10,15]. Common symptoms of the disease may include: fever, cough, fatigue, shortness of breath, sore throat, headache, and conjunctivitis [5,15]. Therefore, it is difficult to distinguish COVID-19 from other respiratory diseases [16,22,31].
The defeat of the gastrointestinal tract, accompanied by diarrhea, nausea and vomiting, is noted in a smaller number of cases. It should be noted that in 80-90% of cases, there is a mild or asymptomatic course of infection, which in about 10% of patients at various times from the moment of infection is realized in a severe course with shortness of breath, hypoxemia and extensive (> 50%) radiological damage to the lung parenchyma. Critical condition with respiratory failure, pneumonia, shock, develops in about 5% of cases, accompanied by a fatal outcome, which almost always occurs as a result of the progression of acute respiratory distress syndrome and multiple organ failure [10,23,26].
Among hospitalized patients, about 10-20% enter the intensive care unit (ICU), 3-10% need intubation, and 2-5% die [30]. There is evidence that the mortality rate from COVID-19 is about 3% [9], which is therefore lower than from SARS-CoV (10%) and MERS-CoV (35%). However, given the relatively recent and rapid spread of COVID-19, it may be too early to determine the actual death rate from this disease. Current data show that the main risk factors for an adverse outcome include age, coronary heart disease, hypertension, diabetes mellitus, and chronic lung disease [13].
Patients with prolonged, delayed onset of the disease pose a high risk of continuing the pandemic and are the cause of a severe epidemiological situation in all countries.
Research Objective: to investigate the age characteristics, concomitant pathology, and timing of the main clinical symptoms of COVID-19 in contact patients.
Research materials
Study design: a retrospective, one-step study. Patient information (clinical data) is extracted from the database of
the integrated medical information system (IMIS) from all regions of Kazakhstan, formed on the basis of electronic medical records (5326) of patients with COVID-19 who were on inpatient treatment from March 13 to June 5, 2020.
Inclusion criteria: positive PCR analysis for the presence of SARS-CoV-2 nucleic acid, no clinical symptoms at the time of examination.
Indicators of descriptive statistics are calculated using the MS Excel analysis package.
Results
We analyzed 5326 electronic medical records of patients with COVID-19, of which 94,4% (n=5011) of patients at the time of laboratory confirmation had a clinical manifestation of COVID-19 of varying severity, the remaining 315 were hospitalized as contact persons with positive PCR SARS-CoV-2, in the course of further monitoring, it was found that 5.6 % of patients realized clinical manifestations of COVID-19 of varying severity during inpatient treatment.
An important task of epidemiological surveillance of infectious diseases for all countries is to identify the population groups that are most actively involved in the epidemic process. Our analysis of the age structure presented in Figure 1 showed that the highest percentage of morbidity was observed among the age group of 20-29 years and amounted to 26,7% of cases (n=84). Significant differences in the proportion of disease in age groups: 30-39 (17,1%), 40-49 years (19,4%), 50-59 years (17,1%) were observed, the same percentage of registered patients aged 10-19 years and 60-69 years was observed in 5,4% respectively, 3,2 % of cases (n=10) COVID-19 was observed in patients older than 80 years, not significantly different from age group of children aged 1-9 years (2,9%) and the minimum number of occurrence of the disease was observed in children under one year and 1.6% (n=5) and among those aged 70-79 years was 1,3% (n=4). Figure 1.
30,00% 25,00%
o 20,00%
ro
(13
S 15,00%
o o
10,00% 5,00% 0,00%
26,70%
5,40%
1,60%. 2,90%
5,40%
1,30%
3,10%
up to 1 1-9 10-19 20-39 30-39 40-49 50-59 60-69 70-79 80 years years years years years years years years years years and old old old old old old old old older
Figure 1. The age characteristics of the patients.
Our data coincide with the results of a study by Russian scientists, where the average age of COVID-19 patients was (46.41 ±20.58) (from March to July 2020). Patients with COVID-19 were characterized by a predominance of mainly middle-aged and elderly people. Most often, COVID-19 was registered in the age groups "40-59 years" and "19-39 years" - 35,7 % (35,5-35,9 %) and 30,8 % (30,6-31.0%), respectively [1]. Figure 2.
Severe degree Extremelysevere 2% degree
moderate degree 36%
Mild degree 61%
Figure 2. Severity of COVID-19 in patients
Of the 315 patients, clinical manifestations of varying severity were observed in 95,6% (n=301) of the patients. Accordingly, the remaining 14 patients did not realize any clinical manifestations and were attributed to asymptomatic viral transmission (4,4%). According to the clinical protocol for the diagnosis and treatment of COVID-19, a complex laboratory and instrumental examination was conducted,
According to the clinical protocol "Coronavirus infection-COVID-19", the characteristic clinical manifestations for this disease are: upper respiratory tract lesions (rhinitis, pharyngitis), lower respiratory tract lesions (COVID-associated pneumonia), extrapulmonary COVID-associated lesions (gastroenteritis, nephritis, myocarditis, olfactory nerve neuritis, meningitis, encephalitis, polyneuropathies, etc.). Among the analyzed patients, as shown in Figure 3,
based on the data of which the severity of the patients was determined (Figure 2). It is revealed that at 61,1% were prevalent lung disease (n=184), moderate degree was observed in 35,9% of patients (n=108), severe degree was noted in 2% of cases (n=6), noteworthy that in 1% of cases (n=3) patients required ICU due to the extremely severe course of the disease, given that all of them belong to the age group of 60 years and older and had a history of comorbidities in diabetes, obesity and hypertension.
As shown in Table 1, the implementation of clinical manifestations in pre-symptomatic patients at the time of hospitalization in most cases, 73 % (n=220), occurred in the first three days of hospitalization, during the first week (from 4-7 days of hospitalization), the manifestations of the disease were noted in 17,9% of cases (n=54), in 7.4% of patients, symptoms appeared in the period from 8 to 14 days of hospital stay, the later onset of symptoms characteristic of COVID-19, the onset of which was registered between 15-23 days in 1,7% of patients (n=5). Figure 3.
the following clinical symptoms were registered with the highest frequency: more than half of the patients 57,1% had an increase in body temperature (n=171), sore throat and cough were observed in every second patient, and amounted to 47,3% and 40,9%, respectively, in significantly less frequent cases - runny nose (12,4%), diarrhea (8,6%), difficulty breathing (6,3%) and muscle pain - in 3,8% of patients. Figure 4
Table 1.
Time of symptoms onset (day).
№ Symptoms Number of Number of
onset (day) cases (abs.) cases(%)
1 1-3 220 73
2 4-7 54 17,9
3 8-14 22 7,4
4 15-23 5 1,7
Total: 301 100%
60,00%
50,00%
о 40,00%
tn
го
Ü 30,00% о
<u
20,00% 10,00% 0,00%
57,10%
40,90%
12,40%
8,60%
6,30%
3,80%
Fever Sore throat Runny nose Cough Muscle pain Diarrhea Dyspnea
Clinical manifestations
Figure 3. Clinical implications in patients with COVID-19.
45,0% 40,0% 35,0%
S> 30,0%
.2 25,0%
c '
I 20,0%
<D
15,0% 10,0% 5,0% 0,0%
38,50%
21,60%
21,10%
15,30% 14,70%
4 5
Time of onset (day)
10%
8,20%
• Fever —Anosmia and hypogeusia Figure 4. Time of onset (day) of fever, olfactory dysfunction and dysgeusia.
The time of onset of the reaction temperature from "presymptomatic" at the time of hospitalization of patients ranged from 2 to 7 days, while of the 171 patients, who had a fever the highest rates of implementation of this symptom of 22,9% (n=39) were observed on the 3rd day of hospitalization, in 21,6% (n=37) notes her onset on 2 day hospital stay, at least, the onset of temperature on day 4, which was 14,7% (n=25), with subsequent growth on day 5 - 20,4% (n=35), there was also a more delayed onset of this sign in the clinic, so on the 6th and 7th day of hospitalization, there was a relatively uniform initial registration of elevated temperature, which was 10.4% (n=18) and 10% (n=17), respectively.
Olfactory dysfunction (OD) - hyposmia and anosmia-is an important symptom of COVID-19 and is increasingly being used as a public health tool to identify COVID-19 patients, in particular asymptomatic carriers, who may unknowingly be the main drivers of the spread of the disease [3]. According to the results of our studies, all patients have a combination and simultaneous onset of OD
and dysgeusia. The highest of these symptoms is noted during the 2nd day of hospitalization, which is 38,5% (n=66) of the total number of patients celebrating the clinical symptom (n=134), some 21,1% (n=36), the changes observed on the 3rd day of hospitalization, 15.3 (n=26) and 16,9% (n=19) changes in the perception of taste and smell appear on 4 and 5 days hospital stay, respectively, OD and dysgeusia 8,2% was observed in patients after a week (6-day) after identifying a positive PCR for SARS-CoV-2.
Given the significant detection rate of OD and dysgeusia, this indicator may increase the sensitivity of COVID-19 screening strategies, in particular, to identify patients at the earliest stages of the disease. Despite the fact that the pathogenetic mechanism of olfactory dysfunction and its clinical characteristics in patients with COVID-19 remain unclear. Multiple cross-sectional studies conducted in the world have shown that the frequency of blood pressure in patients with COVID-19 ranges from 33,9 to 68% with a predominance of women [28]. Figure 5
Figure 5. Background pathology in patients with COVID-19.
Of the 315 contact persons with a positive PCR result for SARS-CoV-2 at the time of hospitalization, 74 were found to have comorbidities. In the structure, diseases of the cardiovascular system prevailed, and amounted to 27%, chronic respiratory diseases were observed in 16,2% of patients, endocrinopathy occupied 24,3%, of which the
share of diabetes mellitus accounted for 8,1%, obesity was three times less (2,7%), with the same frequency: anemia and a burdened allergic background of 10,8%, respectively, concomitant pathology from the kidneys was observed in 9.4% of patients, liver diseases accounted for 2,7%. It should be noted that in 2,7% of cases, COVID-19 occurred
2
3
6
7
during pregnancy and the identified clinical manifestations in some cases occur in combination with each other.
Discussion of the results
Pandemic COVID-19 has caused a huge crash in the world, while molecular biological characteristics and variability of the clinical course, high risk of development of critical conditions, complications and significant mortality level [5].
Contact persons with positive PCR for SARS-CoV-2, and patients with an asymptomatic course of the disease pose a high risk of continuing the pandemic and are the cause of a severe epidemiological situation in all countries. The above data show the importance of proper management of patients with an asymptomatic course of COVID-19. Up-to-date, reliable, and timely data can help decision-makers better understand the situation and implement the necessary measures.
The asymptomatic course of COVID-19 is currently receiving a lot of attention, but its frequency remains unclear. A study conducted by American scientists showed that 55 asymptomatic carriers with confirmed SARS-CoV-2 infection at subsequent admission eventually had different symptoms and mainly a mild course of the disease, asymptomatic infection was noted mainly in young patients aged 18 to 29 years [25]. Another study involving 634 patients infected with COVID-19 on a cruise ship in Japan found that 17.9% of those examined were asymptomatic [20].
The analysis of the age structure in our study showed that the highest percentage (26,7%) of morbidity was observed among the age group of 20-29 years, and relatively the same level was observed in the age categories: 30-39 years (17,1%), 40-49 years (19,4%), 5059 years (17,1%).
In our opinion, the obtained age ratio of COVID-19 cases is associated with the predominance of people of the most working age (20-59 years), and not with the features of SARS-CoV-2, which coincides with the data of Russian scientists [2].
The high rate of human-to-human transmission of SARS-CoV-2 [17] is partly due to the pronounced transmission during the pre-symptomatic course of the disease [11], when infection reaches a peak.
According to British scientists Eggo et. Al., in May 2020, only 20% of children under the age of 18 show symptoms of the disease. According to the results of a meta-analysis conducted by researchers from India co-authored by Meena., 91% (87-95%) of children had a history of contact with a SARS-CoV-2 infected patient. The results of seventeen studies showed that in 23% (17-30%) of cases, patients were asymptomatic. Twenty-three studies (n-1330) reported data on specific symptoms, where fever was the most common clinical sign and was observed in almost half of the patients. 45% of the patients had a cough, and only 11% had rapid breathing, and 4-9% had gastrointestinal manifestations. Most of these patients had mild to moderate disease severity (96%), with a very small proportion of patients having severe manifestations (3%), such as hypoxia, dyspnea, and cyanosis. Only 1% of all clinically confirmed cases were severe (acute respiratory distress syndrome, respiratory failure, shock, encephalopathy, myocardial injury or heart failure, acute kidney injury, etc.).
In the analyzed patients, mild (61,1%) and moderate (35,9%) course of the disease prevailed in terms of severity, but it should be noted that the severe degree occurred in 2% of cases (n=6), while 1% of patients (n=3) needed ICU due to the extremely severe course of the disease, given that this category of patients belong to persons 60 years and older and has a history of concomitant diseases in the form of diabetes, obesity and hypertension.
In a retrospective study by Klopfenstein et. al., 54 (47%) of 114 confirmed COVID-19 patients had anosmia [14]. The study also showed that anosmia in patients usually developed 4.4 days after the onset of SARS-CoV-2 infection with a duration of 8.96 days, while olfactory function in 98% of patients was restored within 28 days [14,19].
In our study, there is an earlier occurrence of OD with the highest rate of these symptoms on day 2 of hospitalization (38,5%), while all patients have a combination and simultaneous onset of OD and dysgeusia.
Data from a multicenter study conducted in patients with laboratory-confirmed COVID-19 infection, who were recruited from 12 European hospitals, showed that a total of 417 patients with mild to moderate COVID-19 were registered. Runny nose and nasal congestion were the most common catarrhal manifestations associated with the disease. While 85.6% and 88.0% of patients reported olfactory and taste dysfunction, respectively. There was a significant association between both disorders (p <0.001). OD appeared earlier than other symptoms in 11,8% of cases [12].
The vast majority of cases of SARS-CoV-2 infection are associated with contact-household transmission of the virus in the families of infected people with asymptomatic forms of COVID-19 [4,6,7,18,21].
According to the clinical Protocol of the Republic of Kazakhstan examination of the contact includes only the definition of PCR for COVID-19, while computer tomography (CT) of the lungs is not provided in the absence of implementation of clinical manifestations, but in individuals with no clinical manifestations, even in case of a positive PCR test may be significant changes in the lung on CT.
According to the author Nicole Varble et al., the importance of the significance of the asymptomatic population of people with a positive SARS-CoV-2 test was revealed, taking into account their study using early chest CT, which can clarify the dynamics of transmission. A better understanding of chest CT in an asymptomatic population with COVID-19 may provide information for predictive modeling or elucidate the potential role of CT as an epidemiological tool to contain or mitigate outbreaks. In their study, chest CT scans were analyzed in initially asymptomatic patients with a positive polymerase chain reaction to SARS-CoV-2. CT results were correlated with clinical and laboratory features and subsequent symptoms to characterize the nature of SARS-CoV-2 virus infection in the outbreak [24].
The importance of screening contact persons remains relevant, and according to Chinese scientists Xingfei Pan et al., in order to prevent and control COVID-19, it is necessary to examine and observe infected SARS-CoV-2 as early as possible, despite the absence of symptoms [29].
Given the ongoing COVID-19 pandemic, it is necessary to conduct similar studies, with an in-depth study of contact persons and patients with an asymptomatic course.
Conclusions
The analysis of the age structure showed that among the studied patients who were admitted without symptoms, as a rule, people of the most working age predominate. The highest percentage (26,7%) of morbidity was observed among the age group of 20-29 years, and relatively the same level was observed in the age categories: 30-39 years (17,1%), 40-49 years (19,4%), 50-59 years (17,1%).
When assessing the severity, it was revealed that 5.6 % of those initially admitted as contacts with positive PCR for SARS-CoV-2 subsequently implemented a clinic during their hospital stay with mild, moderate and severe severity, while 1 % of patients (n=3) needed ICU due to the extremely severe course of the disease.
The study of the relationship of the severity and structure of chronic diseases, showed that the severity of the disease increases with increasing age and presence of comorbidities, among which are prevalent cardiovascular disease (27%), and endocrinopathies (24,3%).
Contact persons with positive PCR for SARS-CoV-2, and patients with an asymptomatic course of the disease pose a high risk of continuing the pandemic and are the cause of a severe epidemiological situation in all countries.
Early detection and monitoring of contacts with COVID-19 allows you to identify patients from the "risk group" and conduct timely treatment, which helps to avoid complications. Patients with a mild course and asymptomatic patients pose a high risk in the continuation of the pandemic and are the cause of a severe epidemiological situation. The results show the importance of early detection, isolation, and monitoring of COVID-19 contacts. This study, with reliable and timely information obtained, contributes to timely preventive and therapeutic and diagnostic measures, which would significantly affect the reduction of deaths among persons of the "risk group".
Authors ' contribution: All authors were equally involved in the research and writing of the article:
Mynzhanova A. - the collection of data, writing of the draft articles, management of resources study.
Baesheva D.A. - scientific guidance, concept and conceptualization of research.
Omarova A.K., KhamitovaM.O., Dauylbaeva A.U. - data set.
Turdalina B.R., Seidullaeva A.J., Altynbekova A.V., Zhuzzhasarova A.A. - scientific management and scientific support article, revision of the draft articles, formal analysis.
Kirpicheva U.A. - statistical processing of the material.
Kushugulova A.R., Kozhakhmetov S.S.-critical analysis, scientific support of the article, revision of the article.
No conflicts of interest were declared. The authors state that this material was not previously submitted for publication in other periodicals. In carrying out this work, there was no funding from third-party organizations and medical representatives.
Information about the publication: no part of this article has been published in other journals and is not under consideration by other publishers.
Литература:
1. Акимкин В.Г., Кузин С.Н., Семененко Т.А., Плоскирева А.А., Дубоделов Д.В., Тиванова Е.В., Пшеничная Н.Ю., Каленская А.В. и др. Гендерно-
возрастная характеристика пациентов. DOI: 10.21055/0370-1069-2020-3-27-35.
2. Акимкин В.Г., Кузин С.Н., Семененко Т.А., Шипулина О.Ю., Яцьшина С.Б., Тиванова Е.В. и др. Закономерности эпидемического распространения SARS-CoV-2 в условиях мегаполиса // Вопросы вирусологии. 2020; 65(4):203-211. DOI: 10.36233/05074088-2020-65-4-203-211.
3. Ahmad R. Sedaghat, Isabelle Gengler, Marlene M. Speth. Review Otolaryngol Head Neck Surg. 2020 Jul;163(1):12-15. doi: 10.1177/0194599820926464. Epub 2020 May 5. Olfactory Dysfunction: A Highly Prevalent Symptom of COVID-19 With Public Health Significance Affiliations expand PMID: 32366160 DOI: 10.1177/0194599820926464.
4. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12 -April 2, 2020. MMWR Morb. Mortal. Wkly Rep. 2020; 69(14):422-26. DOI: 10.15585/mmwr.mm6914e4.
5. Chun М., Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of new coronavirus pneumonia 2019 in Wuhan, China: a descriptive study // Lancet 2020; 395 :507-13.
6. Dhochak N., Singhal T., Kabra S.K., Lodha R. Pathophysiology of COVID-19: why children fare better than adults? // Indian J Pediatr. 2020; 87(7):537-46. DOI: 10.1007/s12098-020- 03322-y.
7. Dong Y., Mo X., Hu Y., Qi X., Jiang F., Jiang Z., Tong S. Epidemiology of COVID-19 among children in China // Pediatrics. 2020; 145(6):e20200702.DOI: 10.1542/peds.2020-0702.
8. Gu H., Xie Z., Li T., Zhang S., Lai C. et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus // Sci Rep.2016. v.6. Р.19840
9. Guan W-j, Ni Z-y, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China . N Engl J Med 2020; 382 : 1708-20.
10. He f., Deng Y., Li V. Coronavirus disease 2019 (COVID-19): what do we know? J Med Virol 2020. 92 (7): 719-725, 14 March 2020.
11. He X., Lau E.H.Y., Wu P. et al (2020) Temporal dynamics in viral shedding and transmissibility of COVID-19 // Nat Med. 10.1038/s41591 -020-0869-5
12. Jerome R Lechien, Carlos M Chiesa-Estomba, Daniele R De Siati, Mihaela Horoi, Serge D Le Bon, Alexandra Rodriguez, Didier Dequanter, Serge Blecic Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Multicenter Study Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6.
13. Jiang F., Deng L., Zhang L., Cai Y., Cheung C.W., Xia Z. Review of clinical characteristics of coronavirus disease 2019 (COVID - 19) // J Gen Intern Med. 2020 May;35(5):1545-1549. doi: 10.1007/s11606-020-05762-w. Epub 2020 Mar 4.
14. Klopfenstein T., Kadiane-Oussou N.J., Toko L., Royer P.Y., Lepiller Q., Gendrin V. Features of anosmia in COVID-19 // Med Mal Infect. 2020 doi:
10.1016/j.medmal.2020.04.006. [pii: S0399-077X(20)30110-4, Apr 17.
15. Lauer S.A., Grantz K.H., Bi K.. et al . Incubation period of coronavirus disease 2019 (COVID-19) from officially registered confirmed cases: assessment and application // Ann Int Med 2020; 172 : 577.
16. Li L.Q., Huang T., Wang Y.Q. et al 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis // J Med Virol. 2020; 92: 577-83.
17. Li Q., Guan X., Wu P., et al. Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia // N Engl J Med. 2020;382:1199-1207. doi: 10.1056/NEJMoa2001316.
18. Luers J.C., Rokohl A.C., Loreck N, Wawer Matos P.A., Augustin M., Dewald F. Olfactory and gustatory dysfunction in coronavirus disease 19 (COVID-19) // Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa525, May 1.
19. Ludvigsson J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults // Acta Paediatr. 2020; 109(6):1088-95. DOI: 10.1111/apa.15270.
20. Mizumoto K., Kagaya K., Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 // Euro Surveill. (2020) 25:2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
21. She J., Liu L., Liu W. COVID-19 epidemic: disease characteristics in children // J. Med. Virol. 2020; 92(7):747-54. DOI: 10.1002/jmv.25807.
22. Singhal T.A. Review of Coronavirus Disease -2019 (COVID-19) // Indian J Pediatr. 2020; 87: 281-6.
23. Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence // J Med Virol. 2020; 92: 548-51.
24. Varble Nicole, Maxime Blain, Michael Kassin, Sheng Xu, Evrim B. Turkbey, Amel Amalou, Dilara Long, Stephanie Harmon et al. Author information Article notes Copyright and License information and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings // Disclaimer Eur Radiol. 2020 Nov 4: 1-12. doi:10.1007/s00330-020-07401-8 PMCID:PMC7610169 PMID:33146796CT
25. Wang Y., Liu Y., Liu L., Wang X., Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China // J Infect Dis. (2020) 221:1770-4. doi: 10.1093/infdis/jiaa119.
26. Wu Z., McGoogan J.M. Characteristics and important lessons of the 2019 coronavirus outbreak (COVID-19) in China: summary of the report of the Chinese center for disease control and prevention on 72314 cases // JAMA 2020; 323 : 1239-42.
27. www.coronavirus2020.kz, (дата обращения: 29.01.2021).
28. Xiangming Meng, Yanzhong Deng, Zhiyong Dai, and Zhisheng Mengc COVID-19 and anosmia: A review based on up-to-date knowledge // Am J Otolaryngol. 2020 September-October; 41(5): 102581. Published online 2020 Jun 2. doi: 10.1016/j.amjoto.2020.102581 PMCID: PMC7265845 PMID: 32563019
29. Xingfei Pan, Dexiong Chen, Yong Xia, Xinwei Wu, Tangsheng Li, Xueting Ou, Liyang Zhou, and Jing Liuf, Author information Copyright and License information Disclaimer Asymptomatic cases in a family cluster with SARS-CoV-2 infection // Lancet Infect Dis. 2020 Apr; 20(4): 410-411. Published online 2020 Feb 19. doi: 10.1016/S1473-3099(20)30114-6 PMCID: PMC7158985 PMID: 32087116
30. Xyz Zhi, Wang Y. et al. Covid-19 pathology data related to acute respiratory distress syndrome // Lancet Resp Med 2020; 8: 420-2.
31. Yang X., Xu Jet al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-center retrospective observational study // Lancet Resp Med 2020; 8: 475-81.
References:
1. Akimkin V.G., Kuzin S.N., Semenenko T.A., Ploskireva A.A., Dubodelov D.V., Tivanova E.V., Pshenichnaja N.Ju., Kalenskaja A.V. et al. Genderno-vozrastnaja harakteristika pacientov. [Gender and age characteristics of patients]. DOI: 10.21055/0370-1069-20203-27-35 UDK 616.98:578.2 [in Russian].
2. Akimkin V.G., Kuzin S.N., Semenenko T.A., Shipulina O.Ju., Jacyshina S.B., Tivanova E.V. et al. Zakonomernosti jepidemicheskogo rasprostranenija SARS-CoV-2 v uslovijah megapolisa. [Patterns of the epidemic spread of SARS-CoV-2 in a megalopolis]. Voprosy virusologii [Questions of virology]. 2020; 65(4):203-211. DOI: 10.36233/0507-4088-2020-65-4-203-211 [in Russian].
3. Ahmad R Sedaghat, Isabelle Gengler, Marlene M. Speth Review Otolaryngol Head Neck Surg. 2020 Jul;163(1):12-15. doi: 10.1177/0194599820926464. Epub 2020 May 5. Olfactory Dysfunction: A Highly Prevalent Symptom of COVID-19 With Public Health Significance Affiliations expand PMID: 32366160 DOI: 10.1177/0194599820926464.
4. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12 -April 2, 2020. MMWR Morb. Mortal. Wkly Rep. 2020; 69(14):422-26. DOI: 10.15585/mmwr.mm6914e4.
5. Chun M., Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of new coronavirus pneumonia 2019 in Wuhan, China: a descriptive study. Lancet. 2020; 395 :507-13.
6. Dhochak N., Singhal T., Kabra S.K., Lodha R. Pathophysiology of COVID-19: why children fare better than adults? Indian J Pediatr. 2020; 87(7):537-46. DOI: 10.1007/s12098-020- 03322-y.
7. Dong Y., Mo X., Hu Y., Qi X., Jiang F., Jiang Z., Tong S. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145(6):e20200702.DOI: 10.1542/peds.2020-0702.
8. Gu H., Xie Z., Li T., Zhang S., Lai C. et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016. v.6. P.19840
9. Guan W-j, Ni Z-y, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 : 1708-20.
10. He f., Deng Y., Li V. Coronavirus disease 2019 (COVID-19): what do we know? J Med Virol 2020. 92 (7): 719-725, 14 March 2020.
11. He X., Lau E.H.Y., Wu P. et al (2020) Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 10.1038/s41591-020-0869-5
12. Jerome R Lechien, Carlos M Chiesa-Estomba, Daniele R De Siati, Mihaela Horoi, Serge D Le Bon, Alexandra Rodriguez, Didier Dequanter, Serge Blecic, Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Affiliations expands. Multicenter Study Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6.
13. Jiang F., Deng L., Zhang L., Cai Y., Cheung C.W., Xia Z. Review of clinical characteristics of coronavirus disease 2019 (COVID - 19). J Gen Intern Med. 2020 May;35(5):1545-1549. doi: 10.1007/s11606-020-05762-w. Epub 2020 Mar 4.
14. Klopfenstein T., Kadiane-Oussou N.J., Toko L., Royer P.Y., Lepiller Q., Gendrin V. Features of anosmia in COVID-19. Med Mal Infect. 2020 doi: 10.1016/j.medmal.2020.04.006. [pii: S0399-077X(20)30110-4, Apr 17.
15. Lauer S.A., Grantz K.H., Bi K. et al . Incubation period of coronavirus disease 2019 (COVID-19) from officially registered confirmed cases: assessment and application. Ann Int Med. 2020; 172 : 577.
16. Li L.Q., Huang T., Wang Y.Q. et al 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020; 92: 577-83.
17. Li Q., Guan X., Wu P., et al. Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-1207. doi: 10.1056/NEJMoa2001316.
18. Luers J.C., Rokohl A.C., Loreck N., Wawer Matos P.A., Augustin M., Dewald F. Olfactory and gustatory dysfunction in coronavirus disease 19 (COVID-19). Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa525, May 1.
19. Ludvigsson J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6):1088-95. DOI: 10.1111/apa.15270.
20. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. (2020) 25:2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
21. She J., Liu L., Liu W. COVID-19 epidemic: disease characteristics in children. J. Med. Virol. 2020; 92(7):747-54. DOI: 10.1002/jmv.25807.
22. Singhal T.A. Review of Coronavirus Disease -2019 (COVID-19). Indian J Pediatr. 2020; 87: 281-6.
23. Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020; 92: 548-51.
24. Varble Nicole, Maxime Blain, Michael Kassin, Sheng Xu, Evrim B. Turkbey, Amel Amalou, Dilara Long, Stephanie Harmon et al. Author information Article notes Copyright and License information and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings. Disclaimer Eur Radiol. 2020 Nov 4: 1-12. doi:10.1007/s00330-020-07401-8 PMCID:PMC7610169 PMID:33146796CT
25. Wang Y., Liu Y., Liu L., Wang X., Luo N., Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis. (2020) 221:1770-4. doi: 10.1093/infdis/jiaa119.
26. Wu Z., McGoogan J.M. Characteristics and important lessons of the 2019 coronavirus outbreak (COVID-19) in China: summary of the report of the Chinese center for disease control and prevention on 72314 cases. JAMA. 2020; 323 : 1239-42.
27. www.coronavirus2020.kz, (дата обращения: 29.01.2021).
28. Xiangming Meng, Yanzhong Deng, Zhiyong Dai, and Zhisheng Mengc COVID-19 and anosmia: A review based on up-to-date knowledge. Am J Otolaryngol. 2020 September-October; 41(5): 102581. Published online 2020 Jun 2. doi: 10.1016/j.amjoto.2020.102581 PMCID: PMC7265845 PMID: 32563019
29. Xingfei Pan, Dexiong Chen, Yong Xia, Xinwei Wu, Tangsheng Li, Xueting Ou, Liyang Zhou, and Jing Liuf, Author information Copyright and License information Disclaimer Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020 Apr; 20(4): 410-411. Published online 2020 Feb 19. doi: 10.1016/S1473-3099(20)30114-6 PMCID: PMC7158985 PMID: 32087116
30. Xyz Zhi, Wang Y. et al. Covid-19 pathology data related to acute respiratory distress syndrome. Lancet Resp Med. 2020; 8: 420-2.
31. Yang X., Xu Jet al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-center retrospective observational study. Lancet Resp Med 2020; 8: 475-81.
Corresponding author:
Mynzhanova Aitolkyn - Master of Medicine, Doctoral student of the Department of Children's Infectious Diseases, NJSC
"Medical University Astana", Nur-Sultan, Republic of Kazakhstan.
Postal code: Republic of Kazakhstan, 000001, Nur-Sultan, Mendesheva str. 46.
E-mail: aiko6a_1901@mail.ru
Mobile phone: +77756006561
